Drug intelligence / Profile preview

AAV-KP1-CAG-tdTomato

Development stage: Unknown
Modality: Gene Therapies
Administration: Intravenous, Intravenous Injection, Retrograde Renal Pelvis Injection, Local Delivery (renal Vein Or Pelvis), Intracochlear

Overview

AAV-KP1-CAG-tdTomato is a recombinant adeno-associated virus (AAV) vector that utilizes the engineered chimeric AAV-KP1 capsid and the CAG promoter to drive expression of the tdTomato fluorescent reporter protein. The AAV-KP1 capsid was selected for its high transduction efficiency in multiple cell types, including primary human islet cells, human embryonic stem cell–derived β cells, hepatocytes, cochlear cells, and renal proximal tubules. The CAG promoter is a strong synthetic promoter that enables high levels of gene expression in mammalian cells. This vector is used as a research tool for gene delivery and expression studies in various tissues and disease models.

Beyond the preview

Go deeper on AAV-KP1-CAG-tdTomato.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAV-KP1-CAG-tdTomato.

Explore the full profile